Regions of the recurrence lesion also showed increased expression of CTNNB1 and tumor marker NY-ESO-1, compared with the primary lesion; however, these regions also exhibited the expression of inflammatory genes, including T-cell markers and checkpoints (CD3, CD8, PD-1, and CD4; figure 3C, D) and markers of other immune cell types (eg, CD20, CD163, and CD56). This evidence concerns the gene CD8A and neoplasm.